Gastric motor effects of triptans: Open questions and future perspectives

Pharmacological Research

Volumn 43, Issue 3, 2001, Pages 205-210

  Cipolla, Giovanna ^a   Sacco, Stefano ^a   Crema, Francesca ^a   Moro, Elisabetta ^a   De Ponti, Fabrizio ^b   Frigo, Gianmario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

5 HT receptors; Antimigraine agents; Dyspepsia; Gastrointestinal motility; Triptans

Indexed keywords

1 [2 (3 FLUOROPHENYL)ETHYL] 4 [3 [5 (1,2,4 TRIAZOL 4 YL) 1H INDOL 3 YL]PROPYL]PIPERAZINE; 1 [2 [4 (4 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N METHYLISOCHROMAN 6 CARBOXAMIDE; 2,3,6,7 TETRAHYDRO 1' METHYL 5 [[2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL) 4 BIPHENYLYL]CARBONYL]SPIRO[FURO[2,3 F]INDOLE 3,4' PIPERIDINE]; 3 (3 DIMETHYLAMINOPROPYL) 4 HYDROXY N [4 (4 PYRIDINYL)PHENYL]BENZAMIDE; 3 [4 (3 CHLOROPHENYL) 1 PIPERAZINYL] 1,1 DIPHENYL 2 PROPANOL; ELETRIPTAN; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; N [4 [5 [3 (2 AMINOETHYL) 1H INDOL 5 YL] 1,2,4 OXADIAZOL 3 YL]BENZYL]METHANESULFONAMIDE; NARATRIPTAN; RIZATRIPTAN; SB 216641; SB 236057; SEROTONIN 1 RECEPTOR; SEROTONIN 1B AGONIST; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

DRUG MECHANISM; DRUG RECEPTOR BINDING; DYSPEPSIA; GASTROINTESTINAL SYMPTOM; HUMAN; MIGRAINE; MOTOR ACTIVITY; NAUSEA; PRIORITY JOURNAL; REVIEW; STOMACH EMPTYING; STOMACH MOTILITY; VOMITING;

EID: 0034956517     PISSN: 10436618     EISSN: None     Source Type: Journal    
DOI: 10.1006/phrs.2000.0766     Document Type: Article

References (69)

1. Sumatriptan: An updated review of its use in migraine
2. Neurogenic versus vascular mechanisms of sumatriptan and ergot alkaloids in migraine
3. Zolmitriptan: A review of its use in migraine
4. Triptans and migraine
5. Pathophysiology of migraine - New insights
6. 1 agonist, sumatriptan
7. Is chest pain after sumatriptan oesophageal in origin?
8. Further evidence that sumatriptan induced chest pain is oesophageal in origin: Effect on oesophageal visceral sensation
9. Novel approaches to the treatment of nausea and vomiting
10. Current and emerging second-generation triptans in acute migraine therapy: A comparative review
11. The triptans. A summary
12. Effect of sumatriptan, a new selective 5HT1-like agonist, on liquid gastric emptying in man
13. Actions of the 5-hydroxytryptamine 1 receptor agonist sumatriptan on interdigestive gastrointestinal motility in man
14. Sumatriptan, a selective 5-HT1receptor agonist, induces a lag phase for gastric emptying of liquids in humans
15. Influence of sumatriptan on gastric fundus tone and on the perception of gastric distension in man
16. Influence of sumatriptan-induced colonic relaxation on the perception of colonic distention in man
17. Sumatriptan inhibits the gastrocolonic reflex in man
18. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man
19. 1 receptor agonism prolongs the cycle length of the migrating motor complex (MMC) in the stomach and duodenum
20. 1 receptor-mediated relaxation of gastric fundus
21. 1B/D receptor antagonist GR127935 of the effect of sumatriptan on canine gastric compliance
22. Effects of sumatriptan on the guinea-pig isolated stomach
23. Serotonin modulation of gastrointestinal motility
24. Irritable bowel syndrome: New agents targeting serotonin receptor subtypes
25. 1B/D receptor agonist sumatriptan and 5-HT in humanisolated coronary artery
26. 1F receptor agonists in human and bovine cerebral arteries: Similarity with human coronary artery
27. 1D receptors
28. A correlation between severity of migraine and delayed gastric emptying measured by an epigastric impedance method
29. Gastric emptying is transiently delayed in migraine-induced dyspepsia
30. Role of impaired gastric accommodation to a meal in functional dyspepsia
31. 1 receptor agonist on gastric accommodation and initial transpyloric flow in healthy subjects
32. Diagnosis and symptomatic treatment of migraine
33. Pathophysiology and pharmacology of migraine. Is there a place for antiemetics in future treatment strategies?
34. Pharmacology of emesis and gastrointestinal motility. Implications for migraine
35. ASHP guidelines on adverse drug reaction monitoring and reporting
36. Principles of signal detection in pharmacovigilance
37. Adverse drug reactions: Definitions diagnosis and management
38. Functional gut disorders: From motility to sensitivity disorders. A review of current and investigational drugs for their management
39. The origin of symptoms on the brain-gut axis in functional dyspepsia
40. Influence of buspirone-induced fundus relaxation on the perception of gastric distention in man
41. 1 agonist, on the frequency of transient lower esophageal sphincter relaxations and gastroesophageal reflux in healthy subjects
42. 1 agonist, increases gastro-oesophageal reflux
43. 1D receptors
44. Naratriptan: Biological profile in animal models relevant to migraine
45. Preclinical studies on the antimigraine drug sumatriptan
46. Pharmacological profile of almotriptan, a novel antimigraine agent
47. 1D receptors
48. 1B/D receptor agonist, in experimental models predictive of antimigraine activity and coronary side-effect potential
49. 1B/1D agonists in acute migraine with special reference to second generation agents
50. Coronary side effect potential of current and prospective antimigraine drugs
51. 1D-receptor agonists rizatriptan (MK-462) and sumatriptan in human isolated coronary arteries: Outcome of two independent studies using different experimental protocols
52. Contractile responses evoked by dihydroergotamine, naratriptan and sumatriptan in the canine isolated coronary artery
53. Naratriptan is effective and well tolerated in the acute treatment of migraine
54. Naratriptan is effective and well tolerated in the acute treatment of migraine
55. A placebo-controlled crossover study of rizatriptan in the treatment of multiple migraine attacks
56. Acute treatment of migraine attacks: Efficacy and safety of a nonsteroidal anti-inflammatory drug, diclofenac-K in comparison to oral sumatriptan and placebo
57. Oral sumatriptan is effective and well tolerated for the acute treatment of migraine
58. 1B/D agonist
59. Rizatriptan vs sumatriptan in the acute treatment of migraine
60. Postmarketing surveillance of sumatriptan in the treatment of acute migraine
61. Oral sumatriptan vs oral rizatriptan: A direct comparative study in the acute treatment of migraine
62. Rizatriptan (maxalt) for the acute treatment of migraine and migraine recurrence
63. Double-blind, placebo-controlled, dose-finding study of rizatriptan in the acute treatment of migraine
64. Comparison of rizatriptan 10 mg vs naratriptan 2.5 mg in migraine
65. 1B/D agonist rizatriptan in migraineurs
66. Clinical safety of 311 C90 (zolmitriptan): Aggregated data from patients and volunteers to date